Blog
RSS FeedPosted by Michael Wonder on 11 Mar 2026
PHARMAC to fund life‑changing treatments for children with cystic fibrosis
11 March 2026 - PHARMAC will fund new treatment options for people living with cystic fibrosis from 1 April 2026. ...
Posted by Michael Wonder on 05 Mar 2026
New proposal aims to reduce complications following a stem cell transplant
5 March 2026 - People who have just had a stem cell transplant could be better protected from a serious ...
Posted by Michael Wonder on 02 Mar 2026
New Zealand Pharmaceutical Schedule - 1 March 2026
1 March 2026 - The March 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 24 Feb 2026
Wegovy and Mounjaro for weight loss not funded
24 February 2026 - Medsafe has recently approved two new medicines as suitable to support weight management. ...
Posted by Michael Wonder on 24 Feb 2026
PHARMAC proposes to widen access to two medicines for people with melanoma
24 February 2026 - PHARMAC is proposing to widen access to two medicines used to treat melanoma, giving people another ...
Posted by Michael Wonder on 18 Feb 2026
PHARMAC proposes funding new treatments that could transform early care for people with chronic lymphocytic leukaemia, a type of blood cancer
18 February 2026 - People in New Zealand living with chronic lymphocytic leukaemia could soon benefit from funded access to ...
Posted by Michael Wonder on 17 Feb 2026
New iron treatment funded for people who have experienced serious reactions
17 February 2026 - From 1 March 2026, PHARMAC will fund ferric derisomaltose (Monofer) in hospitals for people who have ...
Posted by Michael Wonder on 12 Feb 2026
PHARMAC seeking feedback on plans to modernise the Pharmaceutical Schedule
12 February 2026 - PHARMAC has begun work to update the Pharmaceutical Schedule to make it easier to use, faster ...
Posted by Michael Wonder on 11 Feb 2026
PHARMAC confirms changes to simplify biologic medicine funding criteria
11 February 2026 - PHARMAC has confirmed changes to the Special Authority and Hospital Indication Restrictions criteria for four biologic ...
Posted by Michael Wonder on 05 Feb 2026
PHARMAC proposes wider access to a treatment for people with a rare blood cancer
4 February 2026 - People in New Zealand living with a rare type of blood cancer, systemic anaplastic large cell ...
Posted by Michael Wonder on 01 Feb 2026
New Zealand Pharmaceutical Schedule - 1 February 2026
1 February 2026 - The February 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 22 Jan 2026
PHARMAC proposes to fund life changing treatments for people with cystic fibrosis
22 January 2026 - PHARMAC is proposing to fund new treatment options for people living with cystic fibrosis with eligible mutations, ...
Posted by Michael Wonder on 20 Jan 2026
New iron treatment proposed for people who have experienced low phosphate levels
20 January 2026 - PHARMAC is asking for feedback on a proposal to fund a new iron treatment, ferric derisomaltose (Monofer), ...
Posted by Michael Wonder on 12 Jan 2026
PHARMAC funds treatment for rare disorders
12 January 2026 - PHARMAC will fund nitisinone for people with the rare disorders tyrosinaemia type 1 and alkaptonuria from ...
Posted by Michael Wonder on 02 Jan 2026
New Zealand Pharmaceutical Schedule - 1 January 2026
1 January 2026 - The January 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...